Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated. 2016

Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
Department of Biological Sciences, Graduate School of Science and Engineering, Tokyo Metropolitan University, Japan. Electronic address: k_ando@tmu.ac.jp.

Abnormal phosphorylation of the microtubule-associated protein tau is observed in many neurodegenerative diseases, including Alzheimer's disease (AD). AD-related phosphorylation of two tau residues, Ser262 and Ser356, by PAR-1/MARK stabilizes tau in the initial phase of mismetabolism, leading to subsequent phosphorylation events, accumulation, and toxicity. However, the relative contribution of phosphorylation at each of these sites to tau stabilization has not yet been elucidated. In a Drosophila model of human tau toxicity, we found that tau was phosphorylated at Ser262, but not at Ser356, and that blocking Ser262 phosphorylation decreased total tau levels. By contrast, when PAR-1 was co-overexpressed with tau, tau was hyperphosphorylated at both Ser262 and Ser356. Under these conditions, the protein levels of tau were significantly elevated, and prevention of tau phosphorylation at both residues was necessary to completely suppress this elevation. These results suggest that tau phosphorylation at Ser262 plays the predominant role in tau stabilization when PAR-1/MARK activity is normal, whereas Ser356 phosphorylation begins to contribute to this process when PAR-1/MARK activity is abnormally elevated, as in diseased brains.

UI MeSH Term Description Entries
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D010768 Phosphoserine The phosphoric acid ester of serine. Serine Phosphate,Phosphorylserine,Seryl Phosphate,Phosphate, Serine,Phosphate, Seryl
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004331 Drosophila melanogaster A species of fruit fly frequently used in genetics because of the large size of its chromosomes. D. melanogaster,Drosophila melanogasters,melanogaster, Drosophila
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016875 tau Proteins Microtubule-associated proteins that are mainly expressed in neurons. Tau proteins constitute several isoforms and play an important role in the assembly of tubulin monomers into microtubules and in maintaining the cytoskeleton and axonal transport. Aggregation of specific sets of tau proteins in filamentous inclusions is the common feature of intraneuronal and glial fibrillar lesions (NEUROFIBRILLARY TANGLES; NEUROPIL THREADS) in numerous neurodegenerative disorders (ALZHEIMER DISEASE; TAUOPATHIES). tau Protein,Protein, tau,Proteins, tau
D055550 Protein Stability The ability of a protein to retain its structural conformation or its activity when subjected to physical or chemical manipulations. Protein Stabilities,Stabilities, Protein,Stability, Protein
D019943 Amino Acid Substitution The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties. Amino Acid Substitutions,Substitution, Amino Acid,Substitutions, Amino Acid

Related Publications

Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
March 2016, PLoS genetics,
Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
January 2012, PLoS genetics,
Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
September 2013, Neuromolecular medicine,
Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
December 2025, Acta neuropathologica,
Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
January 2013, Journal of Alzheimer's disease : JAD,
Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
June 1993, Neuron,
Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
July 2019, Journal of cellular physiology,
Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
December 2025, Acta neuropathologica,
Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
January 2022, Journal of Alzheimer's disease : JAD,
Kanae Ando, and Mikiko Oka, and Yosuke Ohtake, and Motoki Hayashishita, and Sawako Shimizu, and Shin-Ichi Hisanaga, and Koichi M Iijima
May 2015, Brain : a journal of neurology,
Copied contents to your clipboard!